Comparison of the influence of angiotensin-converting enzyme inhibitor lisinopril and angiotensin II receptor antagonist losartan in patients with idiopathic membranous nephropathy and nephrotic syndrome

References

• Cameron JS. Membranous nephropathy and its treatment. Nephrol Transplant 1992;7(Suppl 1):72–9.
   PubMedGoogle Scholar
• Cattran DC. Membranous nephropathy: quo vadis? Kidney Int 2002;61:349–50.
   PubMed Web of Science ®Google Scholar
• Cattran DC, Pei Y, Greenwood CM, Ponticelli C, Passerini P, Honkanen E. Validation of a predictive model of idiopathic membranous nephropathy: its clinical and research implications. Kidney Int 1997;51:901–7.
   PubMed Web of Science ®Google Scholar
• Geddes CC, Cattran DC. The treatment of idiopathic membranous nephropathy. Semin Nephrol 2000;20:229–308.
   Web of Science ®Google Scholar
• Gansevoort RT, de Zeeuw D, de Jong PE. Long term benefits of the antiproteinuric effect of angiotensin-converting enzyme inhibition in nondiabetic renal disease. Am J Kidney Dis 1993;22:202–6.
   PubMed Web of Science ®Google Scholar
• Zoja C, Donadelli R, Corna D, Testa D, Facchinetti D, Maffi R, The renoprotective properties of angiotensin-converting enzyme inhibitors in a chronic model of membranous nephropathy are solely due to the inhibition of angiotensin II: evidence based on comparative studies with a receptor antagonist. Am J Kidney Dis 1997;29:254–64.
   PubMed Web of Science ®Google Scholar
• Ruggenenti P, Mosconi L, Vendramin G, Moriggi M, Remuzzi A, Sangalli F, ACE inhibition improves glomerular size selectivity in patients with idiopathic membranous nephropathy and persistent nephrotic syndrome. Am J Kidney Dis 2000;35:381–91.
   PubMed Web of Science ®Google Scholar
• Wu S-C, Liu C-P, Chiang H-T, Lin S-L. Prospective and randomized study of the antihypertensive effect and tolerability of three antihypertensive agents, losartan, amlodipine, and lisinopril, in hypertensive patients. Heart Vessels 2004;19:13–8.
   PubMed Web of Science ®Google Scholar
• Fervenza FC, Sethi S, Specks U. Idiopathic membranous nephropathy: diagnosis and treatment. Clin J Am Soc Nephrol 2008;3:905–19.
   PubMed Web of Science ®Google Scholar
• Ponticelli C, Zucchelli P, Passerini P, Cagnoli L, Cesana B, Pozzi C, A randomized trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. N Engl J Med 1989;320:8–13.
   PubMed Web of Science ®Google Scholar
• Ponticelli C, Zucchelli P, Passerini P, Cesana B, Locatelli F, Pasquali S, A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney Int 1995;48:1600–4.
   PubMed Web of Science ®Google Scholar
• Ponticelli C, Altieri P, Scolari F, Passerini P, Roccatello D, Cesana B, A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J Am Soc Nephrol 1998;9:444–50.
   PubMed Web of Science ®Google Scholar
• Mezzano SA, Aros CA, Droguett A, Burgos ME, Ardiles LG, Flores CA, Renal angiotensin II up-regulation and myofibroblast activation in human membranous nephropathy. Kidney Int Suppl 2003;86:S39–45.
   Google Scholar
• Matsuda H, Hayashi K, Homma K, Yoshioka K, Kanda T, Takamatsu I, Differing anti-proteinuric action of candesartan and losartan in chronic renal disease. Hypertens Res 2003;26:875–80.
   PubMed Web of Science ®Google Scholar
• Kunz R, Friedrich Ch, Wolbers M, Mann JFE. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin–angiotensin system on proteinuria in renal disease. Ann Intern Med 2008;148:30–48.
   PubMed Web of Science ®Google Scholar
• Wilmer WA, Rovin BH, Hebert CJ, Rao SV, Kumor K, Hebert LA. Management of glomerular proteinuria: a commentary. J Am Soc Nephrol 2003;14:3217–32.
   PubMed Web of Science ®Google Scholar
• Remuzzi G, Benigni A, Remuzzi A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest 2006;116:288–96.
   PubMed Web of Science ®Google Scholar
• Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE, Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin converting enzyme inhibition – a patient-level meta-analysis. Ann Intern Med 2003;139:244–52.
   PubMed Web of Science ®Google Scholar
• Luño J, Barrio V, Goicoechea MA, González C, de Vinuesa SG, Gómez F. Effects of dual blockade of the renin–angiotensin system in primary proteinuric nephropathies. Kidney Int Suppl 2002;82:S47–52.
   PubMedGoogle Scholar
• Ruilope LM. Renin–angiotensin–aldosterone system blockade and renal protection: angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers? Acta Diabetol 2005;42(Suppl 1):S33–41.
   PubMedGoogle Scholar
• Apperloo AJ, de Zeeuw D, de Jong PE. Short-term antiproteinuric response to antihypertensive treatment predicts long-term GFR decline in patients with non-diabetic renal disease. Kidney Int Suppl 1994;45:S174–8.
   PubMedGoogle Scholar
• Keane WF, Brenner BM, de Zeeuw D, Grunfeld JP, McGill J, Mitch WE, RENAAL Study Investigators. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int 2003;63:1499–507.
   PubMed Web of Science ®Google Scholar
• Ruggenenti P, Mise N, Pisoni R, Arnoldi F, Pezzotta A, Perna A, Diverse effects of increasing lisinopril doses on lipid abnormalities in chronic nephropathies. Circulation 2003;107:586–92.
   PubMed Web of Science ®Google Scholar
• Kyvelou S-M, Vyssoulis G, Karpanou EA, Adamopoulos D, Zervoudaki A, Pietri P, Effects of antihypertensive treatment with angiotensin II receptor blockers on lipid profile: an open multi-drug comparison trial. Hellenic J Cardiol 2006;47:21–8.
   PubMedGoogle Scholar
• Matchar DB, McCrory DC, Orlando LA, Patel MR, Patel UD, Patwardhan MB, Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med 2008;148:16–29.
   PubMed Web of Science ®Google Scholar
• Ruggenenti P, Perticucci E, Cravedi P, Gambara V, Costantini M, Sharma SK, Role of remission clinics in the longitudinal treatment of CKD. J Am Soc Nephrol 2008;19:1213–24.
   PubMed Web of Science ®Google Scholar